Necitumumab is anti-EGFR recombinant mAb and induces fewer allergic reactions due to the absence of murine systems and induction of antibody-dependent cell-mediated cytotoxicity (ADCC) in most cancer cells expressing EGFR (8). Here, EGFR is linked to cancer.